Sunovion is a division of Japan's Sumitomo Dainippon Pharma, which is known for developing a range of neurology and mental health drugs over the last decade or so. Piotr Wnuk 26 June, 2018 ...

The US regulator has approved the first nebulised long-acting muscarinic antagonist for COPD from Sunovion, offering a device that allows patients to breathe normally while taking their medicine.

This includes a novel compound known as SEP-363856, being developed by Sunovion Pharmaceuticals for schizophrenia, which is now in phase 3 clinical trials. The company has a 20-year history in ...

senior director/multichannel marketing at Sunovion Pharmaceuticals. We’re long-term subscribers to WARC and it’s a tool we use extensively. We use it to source case studies and best practice for the ...